Skip to main content
  • Register
  • Help
  • Contact us

Orphazyme AS (ORPHA) DKK1

Sell:35.92 DKK Buy:36.30 DKK Change: 19.09 DKK (34.55%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:35.92 DKK
Buy:36.30 DKK
Change: 19.09 DKK (34.55%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Sell:35.92 DKK
Buy:36.30 DKK
Change: 19.09 DKK (34.55%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Orphazyme A/S, formerly Orphazyme ApS, is a Denmark-based company active within the biopharmaceutical industry. It develops new therapies for the treatment of a family of genetic disorders. The Company's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The Company collaborates with academic institutions in Europe and the United States.

Contact details

Address:
Ole Maaloees Vej 3, Copenhagen N
KOEBENHAVN
2200
Denmark
Telephone:
+ ()
Website:
https://www.orphazyme.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ORPHA
ISIN:
DK0060910917
Market cap:
1.93 billion DKK
Shares in issue:
34.95 million
Sector:
Biotechnology
Exchange:
Copenhagen Stock Exchange
Country:
Denmark
Currency:
Danish Krone
Indices:
n/a

Key personnel

  • Georges Gemayel
    Chairman of the Board
  • Anders Fink Vadsholt
    Interim Chief Executive Officer, Chief Financial Officer
  • Christophe Bourdon
    Chief Executive Officer
  • Bo Hansen
    Deputy Chairman of the Board
  • Thomas Kirkegaard Jensen
    Chief Scientific Officer
  • Thomas Blaettler
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.